Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading
- 1.1k Downloads
Immunotherapy has become one of the greatest advances in medical oncology over the last century; however, the optimal application for the treatment of breast cancer remains an active area of investigation. Modern immunotherapy strategies augment the immune system and ideally, permit durable tumor-specific immune memory. In fact, several monoclonal antibodies that mediate the immune checkpoint receptors have provided the most clinically meaningful improvement for breast cancer patients to date, particularly for the triple negative subtype. Checkpoint blockade as monotherapy has demonstrated some encouraging results, although some combination strategies appear to augment those responses and may be particularly effective when administered earlier in the course of disease. For example, the combination of atezolizumab and nab-paclitaxel as first-line therapy for metastatic triple negative breast cancer demonstrated significant improvements in progression-free survival when compared with chemotherapy alone. Herein, we review the data for immune therapy in breast cancer and highlight promising future directions.
KeywordsBreast cancer Hormone receptor-positive breast cancer HER2 positive breast cancer Triple negative breast cancer Immunotherapy Immune checkpoint inhibitors PD1 PD-L1 CTLA-4 Pembrolizumab Nivolumab Ipilimumab Avelumab Durvalumab Atezolizumab PARP inhibitors BRCA1/2 mutations Tumor-infiltrating lymphocytes
Compliance with Ethical Standards
Conflict of Interest
Jeremy Force has received compensation from Pfizer and Myriad Genetics for service as a consultant and from NanoString Technologies and Genomic Health as a paid speaker.
Jorge Henrique Santos Leal has received compensation from Pfizer, Roche/Genentech, Novartis, and AstraZeneca for service as a consultant and participation on advisory boards. He also received travel accommodations from Pfizer, Roche/Genentech, Novartis, and AstraZeneca in both 2016 and 2017.
Heather L. McArthur has received clinical trial funding from Merck and MedImmune/AstraZeneca; has received drug support from Merck, Bristol-Myers Squibb, and MedImmune/AstraZeneca; has received compensation for participation in advisory boards from Merck, Roche/Genentech, Lilly, Peregrine Pharmaceuticals, TapImmune, Inc., Amgen, Puma, Pfizer, Immunomedics, Syndax, Spectrum Pharmaceuticals, OBI Pharma, Calithera Biosciences, and Celgene; has served as a consultant for Merck, Roche/Genentech (consulting fees waived in 2018), Lilly, Amgen, and Spectrum Pharmaceuticals; served as a guest speaker for Genomic Health and OBI Pharma; and has received reimbursement for travel expenses from Merck, MedImmune/AstraZeneca, Lilly, Amgen, Spectrum Pharmaceuticals, and Celgene.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 11.• Emens LA, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 2018. This study demonstrated that single agent atezolizumab was well tolerated and provided durable clinical benefit in patients with metastatic TNBC. We also learned from this study that metastatic TNBC patients had improved responses when they received atezolizumab earlier.Google Scholar
- 12.• Nanda R, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34(21):2460–7 First trial reporting the safety of a checkpoint inhibitor in breast cancer. Pembrolizumab monotherapy was well tolerated in metastatic TNBC. Response rates were 18.5% in the evaluable TNBC patients.CrossRefGoogle Scholar
- 13.• Rugo HS, et al. Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. Clin Cancer Res. 2018;24(12):2804–11 Pembrolizumab was well tolerated and had modest overall responses mostly in patients with PD-L1+, ER+, HER2- advanced breast cancer.CrossRefGoogle Scholar
- 15.Loibl S, et al. Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer. J Clin Oncol. 2018;Suppl abstract 104.Google Scholar
- 20.Loi S, et al. Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive advanced breast cancer: results from the PANACEA study (IBCSG 45–13/BIG 4–13/KEYNOTE-014). SABCS. 2017;suppl abstract GS2–06.Google Scholar
- 23.Adams S, et al. KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1–positive, previously untreated, metastatic triple-negative breast cancer (mTNBC). Cancer Res. 2018;suppl abstract, PD6–10.Google Scholar
- 28.Domchek SM, Postel-Vinay S, Bang Y-J, et al. An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC). 2017 San Antonio Breast Cancer Symposium. Abstract PD6–11.Google Scholar
- 36.Force J, et al. Recombinant oncolytic poliovirus combined with checkpoint blockade for breast cancer therapy. JCO. 2018;Suppl e12641.Google Scholar
- 38.Tolaney S et al. AACR. Cancer Res 2018;Suppl Abstract PD6–13.Google Scholar
- 39.•• Adams S, Diamond JR, Hamilton E, Pohlmann PR, Tolaney SM, Chang CW, et al. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial. JAMA Oncol. 2018. In this paper, it was found that the combination of atezolizumab and nab-paclitaxel was safe and improved metastatic TNBC outcomes. Importantly, nab-paclitaxel did not impair atezolizumab systemic immune activation.Google Scholar
- 40.•• Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–21 This seminal phase III trial demonstrated a survival advantage in metastatic TNBC patients receiving atezolizumab and nab-paclitaxel. While PFS was improved in all comers, the primary benefit was noted in those with PD-L1+ disease.CrossRefGoogle Scholar
- 48.Loi S, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860–7.CrossRefGoogle Scholar
- 49.Devarakonda S, et al. Tumor mutation burden as a biomarker in resected non-small-cell lung cancer. J Clin Oncol. 2018;JCO2018781963.Google Scholar
- 56.Schmid P, et al. Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): preliminary results from KEYNOTE-173. J Clin Oncol. 2017. 35.15_suppl.556.Google Scholar
- 57.Martin M, e.a. Final results of NeoMONARCH: a phase 2 neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive (HR+), HER2 negative breast cancer (BC). Cancer Res. 2017;SABCS suppl abstract PD5–01. Google Scholar